Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Sr. Marketing Manager, Life Sciences Audience at Elsevier
About the author:
Seeing academic discoveries translated into life-changing applications is exciting--and, even more so, being a part of it. As a senior marketing manager for Life Sciences Audience, I bring a strong understanding of pharmaceutical industry needs, advancing technologies and customer insights to drive the product go-to-market strategy, planning and execution. Everything I write about here is geared towards issues that I deeply care about: open innovation, emerging approaches in data science and the evolving regulatory framework. Feel free to reach out to me about these topics. It is my desire to deliver my understanding and knowledge back to our communities.
Posts by Xuanyan Xu
Posted on July 9th, 2019 in Pharma R&D
Artificial intelligence is more than just a ‘hot topic’ in the pharmaceutical industry—it is actually influencing the way that major industry players and even entire nations are thinking about the future. As more AI-focused companies are launching, and as investment in AI technology is increasing in the US and EU, China is speeding up its efforts to ensure that it can be competitive in this burgeoning area.(more…)
Posted on January 17th, 2019 in Pharma R&D
The partial shutdown of the U.S. government, which began just before the Christmas holiday, has been especially terrible for hundreds of thousands of federal employees who are either furloughed or working without pay. (more…)
Posted on January 15th, 2019 in Pharma R&D
In the pharmaceutical industry, safety protocols are rigorous. Clinical trials, a lengthy and intense part of the drug development process, are deemed absolutely crucial to ensuring the safety and efficacy of new drugs and therapies. There are also many regulations designed to make certain that high standards are maintained during the various trial phases.
Posted on February 9th, 2018 in Pharmacovigilance
A key component of any pharmacovigilance strategy is building search strings that successfully identify potential adverse events, which must be reported to regulatory agencies. If the query returns too narrow a result set, adverse events may be missed. (more…)